SterRx, LLC Issues Voluntary Nationwide Recall of Certain SterRx Products

If your email program has trouble displaying this email, view as a webpage. SterRx, LLC Issues Voluntary Nationwide Recall of Certain SterRx Products SterRx, LLC today announced the voluntary nationwide recall of approximately 240 lots within their expiry period due to equipment and process issues that could lead to a lack of sterility assurance for products intended to be sterile. To date, SterRx, LLC has not received reports of any product complaints or adverse events associated with this issue. SterRx, LLC has initiated this voluntary recall to the hospital pharmacy level out of an abundance of caution. This recall is being conducted with the knowledge of the U.S. Food and Drug Administration. The lot numbers being recalled were distributed to hospitals nationwide from December 2020- October 2021. The products impacted are specifically: lmg/ml Midazolam in 0.9% Sodium Chloride Fentanyl in 0.9% Sodium Chloride lmg/ml Morphine Sulfate in 0.9% Sodium Chloride lmg/ml Morphine Sulfate in 5% Dextrose 125mg Diltiazem HCL in 0.7% Sodium Chloride 125mg Diltiazem HCL in 5% Dextrose Norepinephrine in 0.9% Sodium Chloride Norepinephrine in 5% Dextrose Epinephrine in 0.9% Sodium Chloride Phenylephrine in 0.9% Sodium Chloride 150mEq Sodium Bicarbonate in 5% Dextrose 200mg Succinylcholine Chloride in 0.9% Sodium Chloride

Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA